Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Joost M. Klaase"'
Autor:
Bin B. R. Kroon, Jacoba van der Zee, Omgo E. Nieweg, Eva M. Noorda, Joost M. Klaase, Bart C. Vrouenraets
Publikováno v:
Melanoma Research, 13, 395-399. Lippincott Williams & Wilkins
Melanoma research, 13(4), 395-399. Lippincott Williams and Wilkins
Melanoma research, 13(4), 395-399. Lippincott Williams and Wilkins
The aim of this study was to assess the results of an isolated limb perfusion (ILP) schedule with high dose hyperthermia (42-43 degrees C) and melphalan, applied sequentially in patients with advanced melanoma of the limbs. Seventeen patients with ex
Autor:
Guus Hart, Alexander M.M. Eggermont, Joost M. Klaase, Bin B. R. Kroon, Bart C. Vrouenraets, Omgo E. Nieweg, Bert N. van Geel
Publikováno v:
Journal of the American College of Surgeons, 188(5), 522-530. Elsevier Inc.
Background: The optimal toxic reaction of the normal tissues in perfused limbs after isolated limb perfusion (ILP) is unknown. Theoretically, more severe limb toxicity could reflect a concomitant increased toxic effect to the tumor and improved outco
Publikováno v:
Seminars in Surgical Oncology. 14:224-231
Because a relationship between toxicity and treatment outcome has never been demonstrated for isolated limb perfusion (ILP) with melphalan, it is important to keep the side-effects of the procedure restricted to a minimum. Risk factors for more sever
Autor:
Bart C. Vrouenraets, Joost M. Klaase, Bin B. R. Kroon, Omgo E. Nieweg, E Sonneveld, Joop A. van Dongen, Bert N. van Geel, Alexander M.M. Eggermont
Publikováno v:
European Journal of Surgical Oncology (EJSO). 22:521-527
Systemic exposure to melphalan is minimized during isolated limb perfusion (ILP) by isolating a limb from the rest of the body. Consequently, there should be no toxicity to vital organs. At present systemic toxicity after ILP has not been studied in
Autor:
P Schmitz, Danielle Lienard, J. Vanderveken, B. B. R. Kroon, H. Schraffordt Koops, A. M. M. Eggermont, Joost M. Klaase, F. Rosenkaimer, Ferdy Lejeune, J. Gérain
Publikováno v:
Journal of Cellular Biochemistry. 56:52-61
Recombinant tumor necrosis factor-alpha (rTNF alpha) has potent antitumor activity in experimental studies on human tumor xenografts. However, in humans, the administration of rTNF alpha is hampered by severe systemic side-effects. The maximum tolera
Autor:
A. M. M. Eggermont, J.A. van Dongen, B. B. R. Kroon, A.N. van Geel, Joost M. Klaase, H. R. Franklin
Publikováno v:
Cancer. 71:2990-2994
BACKGROUND: Forty-two patients with measurable recurrent melanoma of the lower limb were treated according to a double-perfusion schedule. METHODS: To assess the advantage of this schedule compared with that of a single-perfusion treatment, a retrosp
Autor:
Bart C. Vrouenraets, Joost M. Klaase, S. A. Van De Merwe, A. N. van Geel, J. van der Zee, J.A. van Dongen, A. M. M. Eggermont, B. B. R. Kroon
Publikováno v:
Oncology Research and Treatment. 16:163-169
In this overview the Amsterdam/Rotterdam ‘controlled’ normothermic (tissue temperatures 37-38 °C) perfusion technique is described. The benefit of the widely used so-called ‘mild’ hyperthermia (39-40°C) is queried. A plea is made to report
Autor:
H. R. Franklin, Bin B. R. Kroon, Joost M. Klaase, Bert N. van Geel, Joop A. van Dongen, Alexander M.M. Eggermont
Publikováno v:
European Journal of Cancer. 29:325-328
From 1985 to 1990 43 patients with measurable locally inoperable or recurrent melanoma of the lower limb were treated according to a double perfusion schedule. The dose of melphalan given in the first perfusion was low (6 mg/l; 1 h; normothermic) in
Publikováno v:
Melanoma Research. 2:407-410
Regional perfusion therapy of melanoma is followed by an apparent decrease in lymph node metastases. When regional isolated perfusion is performed by cannulating the blood vessels at the iliac level, at least the middle and distal parts of the inguin
Publikováno v:
British Journal of Cancer
In 14 consecutive patients with recurrent melanoma of the lower limb a total of 35 biopsies were taken at the end of perfusion treatment to assess melphalan tissue concentrations in tumour, skin/subcutis and muscle tissue. In tumour tissue (n = 12) t